Analysis of transmitted HIV drug resistance from 2005 to 2015 in Victoria, Australia: a comparison of the old and the new

Baseline genotyping is part of standard-of-care treatment

Jodie D'Costa; Megan Gooey; Nicole Richards; Rizmina Sameer; Elaine Lee; Doris Chibo

2017

Scholarcy highlights

  • Baseline genotyping is part of standard-of-care treatment
  • Attention is typically focused on determining whether resistance to the protease inhibitors and reverse transcriptase inhibitors occurs
  • PI and RTI drug resistance genotyping was performed on blood samples collected between 2005 and 2015 from 772 treatment-naïve Victorian patients infected with HIV within the previous 12 months
  • In the period 2005–10, 39 of 343 patients had at least one PI- or RTI-associated mutation, compared with 34 of 429 during the period 2011–15
  • Compared with 2005–10, during 2011–15 there was a significant decline in the prevalence of the non-nucleoside-associated mutation K103N and the nucleoside-associated mutations at codons M41 and T215
  • One patient was detected with a major INI resistance mutation, namely G118R
  • We acknowledge their continuing connection to their culture, their contribution to our shared knowledge, and pay our respects to their Elders past and present

Need more features? Save interactive summary cards to your Scholarcy Library.